eTect is a Gainesville, Florida-based technology company that develops applications for a novel in-vivo wireless communications platform. Its core product is a capsule that emits a digital wireless message when ingested to enable real-time monitoring of medication compliance. The company’s mobile platform aims to provide a deeper understanding of patients' medication-taking behavior. eTect raised a funding round from The Florida Technology Seed Capital Fund, LLC that was matched with private investment capital; the amount was not disclosed. The company intends to use the funds for market launch and revenue-generation efforts. eTect previously received initial funding through the Institute for Commercialization of Public Research’s Seed Capital Accelerator Program in 2012, which enabled key development milestones and attracted additional capital. eTect has developed a patented technology platform of ultra-low-power wireless integrated circuits, sensor and self-powering circuits, and specialized materials to deliver low-cost short-range wireless sensors and readers. Its platform extends the Internet to ingestible and disposable devices such as pills (ID-Cap), diapers, and bandages for medical, commercial, and consumer applications. The company’s first application, ID-Cap, provides real-time indication when a patient has ingested a prescribed medication and is intended to empower patients, improve care, and lower healthcare costs. eTect recently licensed technology developed in collaboration with the University of Florida to enhance future versions of its platform. The company completed a $1.1 million financing round to support an important first-in-human clinical trial of ID-Cap. A funding commitment from the Institute for the Commercialization of Public Research enabled the company to secure the additional capital needed to reach these milestones.

Total raised

$1M

Funding rounds

2

Latest round

Seed

Latest activity

May 2012